Overview

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

Status:
Active, not recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the pharmacokinetic interaction between HL237 and tacrolimus in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Treatments:
Tacrolimus